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Abstract
Mitochondrion is a multi-functional organelle, which plays important role in 
human ovarian cancers. Mitochondrial quantitative proteomics was used to detect, 
identify, and quantify proteins from mitochondrial samples prepared from ovarian 
cancer and normal control ovary tissues. A total of 5115 mitochondrial proteins 
and 1198 mitochondrial differentially expressed proteins (mtDEPs) were identified 
in human ovarian cancer compared to control tissues. Pathway network analysis 
revealed multiple pathway network changes to involve those mitochondrial proteins 
and mtDEPs. These findings provide the scientific data about the role of mitochon-
dria plays in ovarian cancer, and offer the source for discovery of mitochondrial 
biomarker for ovarian cancers.
Keywords: mitochondrial proteome, proteomics, molecular networks, biomarker, 
ovarian cancer
1. Introduction
Mitochondrion is a multi-functional organelle, which is the center of cell energy 
metabolism, cell signaling, and oxidative stress [1, 2]. Mitochondrial dysfunc-
tion is a hallmark in human ovarian cancers, and plays important roles in ovarian 
carcinogenesis, which has been looked as the cause, biomarker, and therapeutic 
target for ovarian cancers [3–5]. First, a study finds mitochondrial morphology is 
significantly changed in ovarian cancers compared to controls. Electron microscopy 
morphology study shows that mitochondria are abundant and large volume in 
ovarian cancer cells and tissues [6, 7]. Second, mitochondrial ribosomal protein-
encoding genes might be the anti-oncogenes to serve as new biomarkers and 
therapeutic targets. For example, bcl-2-interacting mitochondrial ribosomal protein 
L41 (MRPL41) is differentially expressed in carcinomas to associate with various 
epigenetic states [8]. Mitochondrial ribosomal protein S23 (MRPS23) is involved in 
cancer cell proliferation, which might serve as the therapeutic target [9]. MRPS15 
is significantly upregulated in epithelial breast cells and tissues [10]. Mitochondrial 
COX1 is expressed abnormally in multiple cancers [11–13]. Many cancer-relevant 
communication signaling pathways are linked to mitochondrial proteins. Third, 
mitochondria are the center of oxidative stress, which might be the ‘fuel’ center for 
a cancer metabolism [10]. The abnormal energy metabolism, namely the Warburg 
and reverse-Warburg effects, is the important characteristics in cancers [14]. 
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Therefore, mitochondria play important roles in tumorigenesis, proliferation, angio-
genesis, invasiveness, and metastasis of cancer cells [14, 15]. Proteins are the important 
performer in maintaining mitochondrial morphology and functions. It emphasizes 
the important scientific merits of mitochondrial proteomics in ovarian cancer research 
and clinical practice [16–22]. Mitochondrial proteins function in mutually interacted 
molecular pathway network system, which fits the real situation of ovarian cancer that 
is a multi-cause, multi-process, and multi-result disease [23–25]. It is very difficult to 
use single-parameter biomarker to predict, diagnose, and prognostic assess ovarian 
cancer, thus multi-parameter biomarkers or molecule pattern biomarker is necessary 
for ovarian cancer prediction, prevention, and treatment [26, 27]. Mitochondrial 
proteomics is an effective approach to systematically investigate the role of mito-
chondria in ovarian cancer for discovery of reliable mitochondrial protein biomark-
ers to insight into the molecular mechanism and determination of therapeutic target 
to mitochondria for ovarian cancers. Quantitative proteomic methods commonly 
include two-dimensional gel electrophoresis (2DGE) [28, 29] or two-dimensional 
difference in-gel electrophoresis (2D DIGE) [30] comparative proteomics, and gel-
free-based quantitative proteomics [14, 15], for example, isobaric tags for relative 
and absolute quantification (iTRAQ ) [31, 32], tandem mass tag (TMT) [33], or 
label-free-based quantitative proteomics [34, 35], with different advantages and 
disadvantages, respectively. Those quantitative proteomic methods can achieve a 
high-throughput and high-sensitive identification of mitochondrial proteins and 
post-translational modifications. Currently, stable isotopic labeled large-scale 
2DGE coupled with high-sensitivity liquid chromatography-tandem mass spec-
trometry (LC-MS/MS) is able to detect, identify, and quantify up to least 500,000 
protein proteoforms in human tissue proteoforms [36, 37]. iTRAQ , TMT, or 
label-free is commonly coupled with two-dimensional LC-MS/MS (2DLC-MS/MS), 
which enables detect, identify, and quantify up to several thousands of proteins and 
PTMs, even though these gel-free methods are unable to discriminate proteoforms 
and homolog proteins [38].
Ovarian cancer is a malignant cancer with high morbidity and mortality  
[39, 40] and without clear molecular mechanisms and effectively reliable biomark-
ers for its early-stage diagnosis to improve its prognosis. This book chapter used 
iTRAQ-labeled strong cation exchange chromatography (SCX)-LC-MS/MS method 
to detect, identify, and quantify mitochondrial proteins and mitochondrial differ-
entially expressed proteins (mtDEPs) between human ovarian cancer and control 
ovary tissues. The identified mitochondrial proteins and differentially expressed 
proteins were subject to gene ontology (GO) and Kyoto Encyclopedia of Genes and 
Genomes (KEGG) pathway network analysis for revealing pathway network altera-
tion in ovarian cancers compared to controls. Those findings provide the scientific 
data to establish mitochondrial proteomic reference map of ovarian cancer, mtDEP 
profile and the corresponding pathway network alterations to link with ovarian 
cancer pathogenesis, which is the resource for discovery of potential biomarkers 
and mitochondria-targeting drug targets for ovarian cancers.
2. Methods
2.1 Ovarian cancer tissues and preparation of mitochondria protein samples
Seven ovarian cancer tissues and eleven control ovaries with benign gynecologic 
disease were used in this study. Mitochondria were isolated and purified from 
ovarian cancer and control tissues with differential-speed centrifugation and 
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Nycodenz density gradient centrifugation. The purified mitochondria were veri-
fied with electron microscopy, and Western blot with different antibodies specific 
to different subcellular organelles, including COX4I1 (mitochondrion), flotillin-1 
(cytomembrane), GM130 (Golgi apparatus), catalase (peroxisomes), cathepsin B 
(lysosome), and lamin B (cell nucleus). The proteins were extracted from purified 
mitochondrial samples for iTRAQ-labeled quantitative proteomic analysis. The 
detailed procedure was described in our previous publications [14, 15].
2.2 iTRAQ-based quantitative proteomics analysis
The prepared mitochondrial proteins (200 μg/each sample) were treated with 
N-hydroxysuccinimide (SDT), followed by reduction, alkylation, digestion with 
trypsin, and desalination. The tryptic peptide (100 μg/each sample) was labeled 
with iTRAQ reagent, and each sample was labeled three times. The six labeled 
tryptic peptide samples were mixed, followed by peptide fractionation with 
strong cation exchange (SCX) chromatography. Each SCX-fractionated sample 
was subject to LC-MS/MS analysis on a Q Exactive mass spectrometer (Thermo 
Scientific) within a 60-min LC separation gradient to obtain MS/MS data. The 
MS/MS data were used for identity of proteins with MASCOT search engine. 
The iTRAQ reporter-ion intensities were used to quantify each protein and 
determine each mtDEPs. The detailed procedure was described in our previous 
publications [14, 15].
2.3 Bioinformatics and pathway network analysis
The identified proteins and DEPs in mitochondrial samples were subject to 
GO and KEGG pathway enrichment analysis with Cytoscape, and DAVID online 
software (https://david.ncifcrf.gov/home.jsp). Multiple Experiment Viewer 
(https://sourceforge.net/projects/mev-tm4/files/mev-tm4/) was used to make heat 
map. GO analysis included cellular component (CC), molecular function (MF), 
and biological process (BP). PANTHER (http://www.pantherdb.org/) was used to 
further enrich GO CC.
2.4 Validation of mtDEPs and molecular networks in cell models and 
mitochondrial tissues
Ovarian cancer cells TOV-21G and control cells IOSE80 were used to extract 
RNAs and proteins. Quantitative real-time PCR (qRT-PCR) was used to measure the 
mRNA expression levels of GLDC, PCK2, IDH2, CPT2 and HMGCS2 in TOV-21G 
cells compared to IOSE80 cells. Western blot was used to measure the protein expres-
sion levels of GLDC, PCK2, IDH2, CPT2 and HMGCS2 in TOV-21G cells compared 
to IOSE80 cells, and in ovarian cancer mitochondrial samples compared to control 
mitochondrial samples; and β-actin was used as internal standard for Western blot 
analysis.
2.5 Statistical analysis
For GO and KEGG enrichment analyses, p values were corrected with 
Benjamini-Hochberg (FDR) for multiple testing. For qRT-PCR and Western blot, 
the student’s t-test was used to measure between-group difference with SPSS soft-
ware 13.0, and data was presented as the mean ± SD with p < 0.05. Each experiment 
was repeated at least three times.
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3. Results and discussion
3.1 Mitochondrial proteomic profile in human ovarian cancer tissue
iTRAQ-labeling coupled with SCX-LC-MS/MS identified 5115 proteins in mito-
chondrial samples prepared from human ovarian cancer and control ovary tissues, with 
at least one peptide sequence matches (PSMs). All of identified proteins was collected 
in the supplemental Table 1 in our previous publication [15]. Those 5115 proteins 
mainly distributed within pI 3.81–12.25 and molecular weight (MW) 2.6–1158.2 kDa, 
and in multiple cell components including cell junction (0.8%), cell part (42.7%), 
extracellular matrix (0.6%), macromolecular complex (17.8%), organelle (28.2%), and 
synapse (0.3%) (Figure 1). Of them, 2565 (50.14%) were increased, and 2550 (49.86%) 
were decreased in the abundance in ovarian cancers compared to control ovaries. 
Furthermore, statistical significance analysis revealed 1198 mtDEPs in human ovarian 
cancers compared to control ovaries, including 523 (43.66%) upregulated proteins and 
675 (56.34%) downregulated proteins, with fold-change ≥1.5 or ≤−1.5, and p < 0.05. 
Those 1198 mtDEPs were collected in the supplemental Table 1 in our previous publica-
tion [14]. Those mtDEPs might be directly linked to ovarian cancer pathogenesis, and 
the potential resource for biomarkers. From a systemic molecular network angle, one 
must realize that those non-significant difference proteins might be also important in 
ovarian cancer pathogenesis because they might be the hub-molecule in a network, 
because some studies have found that some hub-molecules changed smaller than those 
boundary molecules in a molecular network in a given condition.
3.2 Pathway networks involved in mitochondrial proteins in ovarian cancer
KEGG pathway network analysis revealed 52 statistically significant pathways to 
involve mitochondrial proteins including mtDEPs in ovarian cancers compared to 
Figure 1. 
Subcellular location of 5115 proteins analyzed with PANTHER. Modified from Li et al. [15], with permission 
from Bioscientifica Ltd., copyright 2018.
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Category Term RT Count % P-value Benjamini
KEGG_PATHWAY Lysosome RT 52 1.3 3.70E−02 2.00E−01
KEGG_PATHWAY Peroxisome RT 53 1.5 8.00E−08 4.60E−06
KEGG_PATHWAY Valine, leucine 
and isoleucine 
degradation
RT 41 1.0 1.10E−07 5.50E−06
KEGG_PATHWAY Phagosome RT 77 2.1 1.20E−05 2.90E−04
KEGG_PATHWAY Citrate cycle 
(TCA cycle)
RT 19 0.8 1.80E−07 7.50E−06
KEGG_PATHWAY Oxidative 
phosphorylation
RT 94 2.0 3.40E−07 1.10E−05
KEGG_PATHWAY Glycolysis/
Gluconeogenesis
RT 33 0.8 1.60E−02 1.20E−01
KEGG_PATHWAY Fatty acid 
metabolism
RT 29 0.8 1.90E−03 2.20E−02
KEGG_PATHWAY Prion diseases RT 14 0.6 2.20E−03 2.40E−02
KEGG_PATHWAY Propanoate 
metabolism
RT 13 0.5 1.40E−03 1.60E−02
KEGG_PATHWAY Sulfur 
metabolism
RT 7 0.3 2.90E−03 3.10E−02
KEGG_PATHWAY Pyruvate 
metabolism
RT 15 0.6 5.30E−03 4.90E−02
KEGG_PATHWAY beta-Alanine 
metabolism
RT 11 0.5 3.10E−02 2.00E−01
KEGG_PATHWAY Butanoate 
metabolism
RT 10 0.4 3.30E−02 2.00E−01
KEGG_PATHWAY Tryptophan 
metabolism
RT 13 0.5 3.30E−02 2.00E−01
KEGG_PATHWAY Arginine 
and proline 
metabolism
RT 15 0.6 4.00E−02 2.10E−01
KEGG_PATHWAY Metabolic 
pathways
RT 524 12.6 1.30E−12 1.80E−10
KEGG_PATHWAY Carbon 
metabolism
RT 75 2.2 3.80E−12 3.70E−10
KEGG_PATHWAY 2-Oxocarboxylic 
acid metabolism
RT 9 0.4 4.30E−03 4.30E−02
KEGG_PATHWAY Glutathione 
metabolism
RT 33 0.9 4.90E−05 1.00E−03
KEGG_PATHWAY Glyoxylate and 
dicarboxylate 
metabolism
RT 15 0.6 4.20E−05 9.40E−04
KEGG_PATHWAY Porphyrin and 
chlorophyll 
metabolism
RT 14 0.6 2.10E−02 1.50E−01
KEGG_PATHWAY Ribosome RT 110 3.0 3.00E−20 8.80E−18
KEGG_PATHWAY Biosynthesis of 
antibiotics
RT 124 3.2 3.50E−11 2.60E−09
KEGG_PATHWAY Aminoacyl-tRNA 
biosynthesis
RT 24 1.0 4.30E−04 6.60E−03
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Category Term RT Count % P-value Benjamini
KEGG_PATHWAY Biosynthesis of 
amino acids
RT 41 1.0 1.10E−03 1.50E−02
KEGG_PATHWAY Terpenoid 
backbone 
biosynthesis
RT 10 0.4 7.80E−03 6.60E−02
KEGG_PATHWAY Proteasome RT 30 0.6 3.10E−02 2.00E−01
KEGG_PATHWAY Protein digestion 
and absorption
RT 24 1.0 2.30E−02 1.60E−01
KEGG_PATHWAY Fatty acid 
degradation
RT 27 0.7 5.30E−03 5.00E−02
KEGG_PATHWAY Protein 
processing in 
endoplasmic 
reticulum
RT 86 2.4 3.20E−07 1.10E−05
KEGG_PATHWAY PPAR signaling 
pathway
RT 20 0.8 1.60E−02 1.20E−01
KEGG_PATHWAY ECM-receptor 
interaction
RT 46 1.3 2.00E−04 3.20E−03
KEGG_PATHWAY Pentose 
phosphate 
pathway
RT 11 0.5 1.90E−02 1.40E−01
KEGG_PATHWAY Focal adhesion RT 88 2.3 1.30E−03 1.70E−02
KEGG_PATHWAY Protein export RT 19 0.5 3.00E−03 3.10E−02
KEGG_PATHWAY Parkinson’s 
disease
RT 97 2.1 1.20E−06 3.30E−05
KEGG_PATHWAY Alzheimer’s 
disease
RT 99 2.3 3.60E−06 9.40E−05
KEGG_PATHWAY Huntington’s 
disease
RT 101 2.3 5.30E−05 1.00E−03
KEGG_PATHWAY Amoebiasis RT 36 1.5 5.60E−05 1.00E−03
KEGG_PATHWAY Complement 
and coagulation 
cascades
RT 26 1.1 1.20E−04 2.10E−03
KEGG_PATHWAY Viral myocarditis RT 21 0.9 9.10E−04 1.30E−02
KEGG_PATHWAY Cardiac muscle 
contraction
RT 25 1.0 1.30E−03 1.60E−02
KEGG_PATHWAY Staphylococcus 
aureus infection
RT 18 0.8 7.60E−03 6.70E−02
KEGG_PATHWAY Bacterial 
invasion of 
epithelial cells
RT 38 1.0 1.10E−02 9.00E−02
KEGG_PATHWAY Vasopressin-
regulated water 
reabsorption
RT 15 0.6 1.30E−02 1.10E−01
KEGG_PATHWAY Arrhythmogenic 
right ventricular 
cardiomyopathy 
(ARVC)
RT 21 0.9 1.50E−02 1.10E−01
KEGG_PATHWAY Platelet 
activation
RT 58 1.3 3.40E−02 2.00E−01
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control ovaries (Table 1 and Figure 2), including phagosome, peroxisome, valine, 
leucine and isoleucine degradation, lysosome, fatty acid metabolism, citrate cycle 
(TCA cycle), oxidative phosphorylation, glycolysis/gluconeogenesis, metabolic 
Category Term RT Count % P-value Benjamini
KEGG_PATHWAY Regulation 
of actin 
cytoskeleton
RT 87 2.0 3.50E−02 2.00E−01
KEGG_PATHWAY Legionellosis RT 16 0.7 3.70E−02 2.10E−01
KEGG_PATHWAY Toxoplasmosis RT 29 1.2 4.50E−02 2.30E−01
KEGG_PATHWAY Systemic lupus 
erythematosus
RT 32 1.3 4.90E−02 2.50E−01
Modified from Li et al. [15], with permission from Bioscientifica Ltd., copyright 2018.
Table 1. 
52 statistically significant KEGG pathways enriched from 5115 proteins in ovarian cancers.
Figure 2. 
52 statistically significant KEGG pathways enriched from 5115 proteins in ovarian cancers. Modified from Li 
et al. [15], with permission from Bioscientifica Ltd., copyright 2018.
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pathways, carbon metabolism, glyoxylate and dicarboxylate metabolism, gluta-
thione metabolism, propanoate metabolism, sulfur metabolism, 2-oxocarboxylic 
acid metabolism, pyruvate metabolism, porphyrin and chlorophyll metabolism, 
beta-alanine metabolism, butanoate metabolism, tryptophan metabolism, arginine 
and proline metabolism, ribosome, protein processing in endoplasmic reticulum, 
biosynthesis of amino acids, aminoacyl-tRNA biosynthesis, proteasome, protein 
Accession 
number
Protein name Gene 
name
Coverage 
(%)
Unique 
peptides
PSMs Ratio 
(T/N)
t-test 
p-value
Q8IVP5 FUN14 domain-
containing 
protein 1
FUNDC1 10.97 1 1 1.16 4.82E−2
B4E164 cDNA 
FLJ56613, 
highly similar 
to Serine/
threonine-
protein kinase 
TBK1 (EC 
2.7.11.1)
TBK1 2.42 1 1 1.25 1.12E−2
O60313 Dynamin-
like 120 kDa 
protein, 
mitochondrial
OPA1 51.15 44 130 1.19 3.72E−4
Q99623 Prohibitin-2 PHB2 81.61 24 220 1.26 4.44E−4
B4E3V2 cDNA 
FLJ52854, 
highly similar to 
Sequestosome-1
p62 10.47 1 1 1.10 1.96E−1
H0YBC7 BCL2/
adenovirus E1B 
19 kDa protein-
interacting 
protein 3-like 
(Fragment)
BNIP3L 
(NIX)
9.19 1 2 0.77 2.31E−3
A0A0S2Z5I6 Optineurin 
isoform 3
OPTN 7.94 2 2 0.62 1.01E−2
E7EU96 Casein kinase II 
subunit alpha
CSNK2A1 
(CK)
25.45 6 8 0.84 1.20E−2
Q96HS1 Serine/
threonine-
protein 
phosphatase 
PGAM5, 
mitochondrial
PGAM5 32.53 10 37 1.49 3.32E−3
B7Z737 cDNA 
FLJ52784, 
highly similar 
to Bcl-2-like 13 
protein
Bcl2-L13 13.17 2 2 0.81 3.99E−2
PSMs  =  peptide sequence matches; MW  =  molecular weight; Ratio (T/N)  =  ratio of tumors to normal controls. 
Reproduced from Li et al. [15], with permission from Bioscientifica Ltd., copyright 2018.
Table 2. 
Mitophagy adaptors and regulatory molecules involved the identified proteins in ovarian cancer biological 
system.
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digestion and absorption, ECM-receptor interaction, focal adhesion, protein 
export, signaling pathway, complement and coagulation cascades, platelet acti-
vation, PPAR pentose phosphate pathway, fatty acid degradation, vasopressin-
regulated water reabsorption, and regulation of actin cytoskeleton. Those pathway 
systems provided an overall molecular network changes in ovarian cancers, which 
might be important in ovarian cancer pathogenesis.
Among those altered pathway systems, especially interested is that mitophagy 
pathway and energy metabolism pathway were significantly changed in ovarian 
cancers compared to controls. The changed mitophagy pathway in ovarian cancer 
included phagosome, peroxisome, valine, leucine and isoleucine degradation, 
lysosome, and fatty acid metabolism pathways [15]. Mitophagy is to engulf any 
Figure 3. 
Energy metabolism pathway changed in ovarian cancer. Reproduced from Li et al. [14], with permission from 
Elsevier Inc., copyright 2018.
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material in autophagosome, and subsequently fuses with lysosomes to release 
high-energy substance such as fatty acid and amino acid. Autophagosome also com-
monly contains mitochondria, proteins, or peroxisome. Mitophagy processes are 
involved in autophagy machinery, mitophagy adaptors, and regulatory molecules 
such as Bcl2-L12, p62, OPTN, prohibitin 2, OPA1, CK, PGAM5, BNIP3L(NIX), 
and FUNDC1 (Table 2). These findings were consistent with previous studies. The 
changed energy metabolism pathway in ovarian cancers included citrate cycle (TCA 
cycle), oxidative phosphorylation, and glycolysis (Figure 3) [14], and the impor-
tant molecules were significantly changed in three energy metabolism pathways, 
including PFKM, PKM, PDHB, CS, and IDH2 (Table 3). It clearly demonstrated the 
Warburg and reverse-Warburg effects coexisted in ovarian cancers.
Accession no. Protein Unique 
peptide
Coverage 
(%)
PSMs Ratio 
(T/N)
p value  
(t test)
Q01813 Phosphofructokinase, 
platelet (PFKP)
1.90 2.28E−02
P11177 Pyruvate 
dehydrogenase E1 
component subunit 
beta (PDHB)
14 52.92 79 1.51 3.25E−03
A0A024R5Z9 Pyruvate kinase 
(PKM)
2.38 1.50E−04
O43837 Isocitrate 
dehydrogenase 
[NAD] subunit beta 
(IDH3B)
13 41.56 43 1.75 8.69E−03
B4DJV2 Citrate synthase (CS) 13 26.93 73 1.59 4.65E−03
P50213 Isocitrate 
dehydrogenase 
[NAD] subunit alpha 
(IDH3A)
18 47.81 53 1.60 2.27E−02
P48735 Isocitrate 
dehydrogenase 
[NADP] (IDH2)
27 56.64 355 2.02 2.07E−03
A0A0A0QN99 Cytochrome b 
reductase 1 (CYB)
14 4.21 4 1.71 7.60E−03
Q9ULD0 2-oxoglutarate 
dehydrogenase-like 
(OGDHL)
13 26.83 58 1.55 1.25E−03
A0A096WB60 NADH-ubiquinone 
oxidoreductase chain 
5 (MT-ND5)
1 5.14 6 0.38 3.34E−04
P07919 Cytochrome b-c1 
complex subunit 6 
(QCR 6)
5 51.65 18 1.59 1.63E−02
A0A059T3A1 NADH–ubiquinone 
oxidoreductase chain 
2 (MT-ND2)
1 4.61 2 0.38 6.03E−04
P38919 Eukaryotic initiation 
factor 4A-III 
(EIF4AIII)
4 11.92 9 0.71 1.48E−02
Modified from Li et al. [14], with permission from Elsevier Inc., copyright 2018.
Table 3. 
Differentially expressed glycolysis/Kreb’s cycle/mitochondrial respiratory chain/RNA binding proteins in EOC.
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3.3 Potential biomarkers for ovarian cancers
Those 5115 mitochondrial proteins including 1198 mtDEPs were the resource of 
potential biomarkers for ovarian cancers. For example, mtDEPs in mitophagy path-
way and energy metabolism pathway might be effective biomarkers and therapeutic 
targets for ovarian cancer. Five mtDEPs, including GLDC, PCK2, and IDH2 in 
peroxisome pathway, CPT2 in fatty acid degradation pathway, and HMGCS2 in 
the valine, leucine and isoleucine degradation pathway were further validated by 
qRT-PCR and Western blot in ovarian cancer cells compared to normal control cells 
(Figure 4A and B), and by Western blot in the ovarian cancer tissue mitochondrial 
samples (Figure 4C). These results also confirmed the results of iTRAQ quantita-
tive proteomics.
4. Conclusions
iTRAQ-labeled SCX-LC-MS/MS quantitative proteomics was an effective method 
to detect, identify, and quantify mitochondrial proteins and mtDEPs in mitochon-
drial samples prepared from human ovarian cancer and control ovary tissues. Totally 
5115 mitochondrial proteins including 1198 mtDEPs were identified in ovarian 
Figure 4. 
Validation of potential biomarkers (GLDC, PCK2, IDH2, CPT2 and HMGCS2) in ovarian cancer cell model 
with qRT-PCR (A) and Western blot (B), and in human mitochondrial samples with Western blot (C). 
β-actin was used as internal standard. Reproduced from Li et al. [15], with permission from Bioscientifica Ltd., 
copyright 2018.
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cancers, and 52 statistically significant pathways were identified to involve those 
mtDEPs. More interested is that this study found mitophagy pathway (phagosome, 
peroxisome, valine, leucine and isoleucine degradation, lysosome, and fatty acid 
metabolism), and energy metabolism pathways (citrate cycle, oxidative phosphory-
lation, and glycolysis) were significantly changed in ovarian cancers. The important 
molecules Bcl2-L12, p62, OPTN, prohibitin 2, OPA1, CK, PGAM5, BNIP3L(NIX), 
and FUNDC1 in mitophagy pathway, and PFKM, PKM, PDHB, CS, and IDH2 in 
energy metabolism pathways were significantly changed. It clearly demonstrated 
the changed mitophagy and energy metabolism pathways played important roles in 
ovarian cancers. These findings provide the large-scale proteomic variation profiles 
and molecular network alterations for ovarian cancer, which are the important sci-
entific data to insight into the roles of mitochondrial dysfunction in ovarian cancer.
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TMT tandem mass tag
2DGE two-dimensional gel electrophoresis
2D DIGE two-dimensional difference in-gel electrophoresis
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